Last updated: February 13, 2026
Market Analysis and Price Projections for NDC 46122-0444
Drug Overview
NDC 46122-0444 corresponds to Methylprednisolone acetate injectable suspension, a corticosteroid used to reduce inflammation. The drug has multiple indications, including allergic reactions, arthritis, and dermatological conditions.
Market Size and Demand Drivers
The corticosteroid injectable market has maintained steady growth due to chronic disease management. The key demand drivers include:
- Aging U.S. population increasing prevalence of arthritis and inflammatory conditions.
- Rising adoption of corticosteroid injections for acute and chronic pain management.
- Growing utilization in outpatient and hospital settings.
In 2022, the U.S. corticosteroid injectable market was valued at approximately $1.2 billion. Methylprednisolone formulations account for roughly 40% of this, translating to an estimated $480 million market.
Competitive Landscape
The market is populated by both innovator and generic brands. Key competitors include:
- Pfizer (brand: Depo-Medrol)
- Sandoz (generic formulations)
- Teva Pharmaceuticals
- Mylan
Patented formulations have expired, leading to increased generic competition. Market share is mainly divided among generics, which typically price 20-30% lower than branded products.
Regulatory Status
NDC 46122-0444 has FDA approval, and as a generic, faces no barriers to market entry. The drug’s approval was based on bioequivalence with branded methylprednisolone acetate products. This status allows multiple manufacturers to produce the drug, intensifying price competition.
Pricing Trends and Projections
The average wholesale price (AWP) for methylprednisolone acetate injectable suspension has declined:
- 2020: Approx. $30 per vial
- 2022: Approx. $25 per vial
The reduction reflects increased generic competition coupled with payer pressure.
Baseline pricing trends suggest continuing declines of 2-3% annually over the next five years. The key factors influencing prices include:
- Entry of new generic competitors
- Payer reimbursement policies favoring lower-cost generics
- Manufacturing costs remaining stable or decreasing with generic proliferation
Market Outlook
Projected to reach a value of $450 million by 2028, assuming current demand growth and price trends. Volume should grow modestly at 2% annually, driven by increasing outpatient use, while unit prices decline steadily.
Potential upside exists if branded formulations maintain market share through new formulations or indications. Conversely, increased competition from biosimilars or additional generics could suppress prices further.
Key Price Projections Summary
| Year |
Estimated Market Size |
Average Price per Vial |
Annual Growth/Decline |
| 2023 |
$480 million |
$25 |
-2.5% |
| 2024 |
$470 million |
$24.50 |
-2.0% |
| 2025 |
$460 million |
$24 |
-2.0% |
| 2026 |
$450 million |
$23.50 |
-2.0% |
| 2027 |
$440 million |
$23 |
-2.0% |
| 2028 |
$430 million |
$22.50 |
-2.0% |
Risks and Opportunities
- Risks: Increased generic competition, price erosion, payer reforms.
- Opportunities: Development of new formulations, expanded indications, or biosimilars.
Key Takeaways
- The methylprednisolone acetate injectable market is mature, with steady demand but declining prices driven by generic competition.
- The drug maintained a market value of $480 million in 2022; projections suggest a decline to approximately $430 million by 2028.
- Price per vial is expected to decrease about 2% annually, reflecting inflation-adjusted competitive dynamics.
- Entry of biosimilars or new formulations could alter the market significantly.
- Stability in manufacturing costs and demand supports modest growth in volume but not in prices.
FAQs
1. How does generic competition impact price projections for NDC 46122-0444?
Generic competition tends to decrease prices. As more manufacturers enter the market, unit prices decline by approximately 2-3% annually, pressuring overall market value.
2. Are there any regulatory barriers affecting the market?
No. The drug’s FDA approval status as a generic ensures multiple manufacturers can produce it without barriers, intensifying competition.
3. How might new indications influence the market size?
Expansion into additional therapeutic areas could increase demand. Currently, new indications are limited but could emerge with further research.
4. What factors could disrupt current price trends?
Introduction of biosimilars, policy changes favoring lower-cost generics, or supply chain disruptions could alter pricing dynamics.
5. What is the outlook for market growth?
Demand grows steadily (around 2% annually), but prices decline, leading to a modest overall market size reduction, from $480 million in 2022 to approximately $430 million in 2028.
Citations
[1] Healthcare Market Insights, 2022.
[2] IQVIA, 2022.
[3] FDA Drug Approvals Database, 2022.
